Vitaeris Inc.
14 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
14
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 9, 2027The maintenance fee for Antibodies to IL-6 and use thereof (US 10,344,086) comes due Jan 9, 2027. Unpaid by Jul 9, 2027, it lapses early.
- 1 fee due May 28, 2027The maintenance fee for Treatment or prevention of diseases and disorders associated with cells that express IL-6 with Anti-IL-6 antibodies (US 11,827,700) comes due May 28, 2027. Unpaid by Nov 29, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,913,794 | Antibodies to IL-6 and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,725,509 | Expression Vectors Containing Isolated Nucleic Acids Encoding Anti-Human IL-6 Antibody In force · Medium confidence | In force | Medium confidence | |
| US 9,834,603 | Antibodies to IL-6 and Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 10,227,404 | Antagonists of IL-6 to Raise Albumin And/Or Lower CRP In force · Medium confidence | In force | Medium confidence | |
| US 10,233,239 | Isolated Host Cells Expressing ANTI-IL-6 Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 10,344,086 | Antibodies to IL-6 and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,759,853 | Antibodies to IL-6 and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 8,178,101 | Use of ANTI-IL-6 Antibodies Having Specific Binding Properties to Treat Cachexia In force · Medium confidence | In force | Medium confidence | |
| US 8,062,864 | Nucleic Acids Encoding Antibodies to IL-6, and Recombinant Production of ANTI-IL-6 Antibodies In force · Medium confidence | In force | Medium confidence | |
| US 9,741,198 | Gaming Device with Special Symbol In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 14: 14 patents in force now held by others · 29 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 2 abandoned · 1 no status recorded